Table 1 Baseline characteristics of patients before starting medication with a SGLT2 inhibitor
n | 21 |
Year of age | 57.7 ± 14.5 |
Male (n) | 12 (57.1%) |
Months in clinical course | 34.6 ± 28.0 |
Systolic blood pressure (mmHg) | 131.7 ± 14.6 |
Diastolic blood pressure (mmHg) | 81.9 ± 10.0 |
Body mass index (BMI, kg/m2) | 28.3 (26.1, 31.6) |
Administration of anti-hypertensive agents (%) | 18 (85.7%) |
Angiotensin II receptor blockers (ARB) | 15 (71.4%) |
Angiotensin-converting enzyme Inhibitors (ACEi) | 1 (4.8%) |
Calcium channel blockers (CCB) | 13 (61.9%) |
β-blockers | 4 (19.0%) |
Diuretics | 5 (23.8%) |
Loop diuretic | 2 (9.5%) |
Thiazide diuretic | 3 (14.3%) |
Administration of oral hypoglycemic agents | 6 (28.6%) |
Sulfonyl-ureas (SU) | 2 (9.5%) |
Dipeptidyl peptidase-4 inhibitors (DPP4i) | 1 (4.8%) |
Biguanides | 3 (14.3%) |
Thiazolidine derivatives | 1 (4.8%) |
α-Glucosidase inhibitors (α-GI) | 1 (4.8%) |
Administration of lipid-lowering agents | 14 (66.7%) |
Statins | 14 (66.7%) |